Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2004

Adkins MW, Howar SR, Tyler JK. Chromatin disassembly mediated by the histone chaperone Asf1 is essential for transcriptional activation of the yeast PHO5 and PHO8 genes. Mol Cell. 2004;14(5):657-66.

Pachori AS, Melo LG, Zhang L, Loda M, Pratt RE, Dzau VJ. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun. 2004;313(3):528-33.

Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, J Kilby M, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis. 2004;189(6):1075-83.

Chae S-, Paik J-, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest. 2004;114(8):1082-9.

Huang X, Di Liberto M, Cunningham AF, Kang L, Cheng S, Ely S, et al. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A. 2004;101(51):17789-94.

Yemelyanova AV, Winter W, Seidman JD. Venous thrombosis in the broad ligament: is it a predictor of postoperative pulmonary embolism in gynecological cancer patients? A case-control study. Int J Gynecol Pathol. 2004;23(2):176-9.

Baran JL, Magro CM, King MA, Williams TE, Ross P. Atypical thymoma: a report of seven patients. Ann Thorac Surg. 2004;78(2):411-6.

Shah NM, Pisapia DJ, Maniatis S, Mendelsohn MM, Nemes A, Axel R. Visualizing sexual dimorphism in the brain. Neuron. 2004;43(3):313-9.

Browne T-, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004;35(12):1462-8.

Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. 2004;100(9):1814-22.